← Leaderboards
Abigail Pulsipher
Glycomira, Llc
$2,897,859
Attributed
$4,299,698
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1000K · FY2016–24$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,299,698 · 3
By mechanism
R44$3,406,812 · 1
R41$595,272 · 1
R43$297,614 · 1
Top collaborators
- Jeremiah Andrew Alt4 shared
- Glenn D Prestwich1 shared
Most similar at Glycomira, Llc
Same institution · by research overlap
- Jeremiah Andrew Alt$1,302,634
- Justin Rodney Savage$2,775,433
Others in their field
Top investigators on “Chronic Rhinosinusitis”
- Robert P Schleimer · Johns Hopkins University$21,245,149
- Andrew P Lane · Johns Hopkins University$13,913,440
- Hirohito Kita · Mayo Clinic Arizona$11,062,767
- Joshua A Boyce · Brigham And Women'S Hospital$10,723,666
- Timothy L Smith · Medical College Of Wisconsin$6,462,008
- Bruce K Tan · Northwestern University At Chicago$5,888,116
Research focus
Chronic RhinosinusitisSinusQuality Of LifeAffectInflammatoryCellsOperative Surgical ProceduresTissuesInfiltrationMedicalAmericanEosinophilCostGuidelinesAnimalsMediatingGlycosaminoglycansIrrigationEffective TherapyInflammationImmuneDoseInflammation MediatorsComplex
Grant awards (7)
Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis$290,351
R41 · FY2024 · AI · contact PI
Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis$304,921
R41 · FY2023 · AI · contact PI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$999,953
R44 · FY2021 · AI · contact PI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$783,698
R44 · FY2020 · AI · contact PI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$841,614
R44 · FY2019 · AI · contact PI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$781,547
R44 · FY2018 · AI · contact PI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$297,614
R43 · FY2016 · AI · contact PI